A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer’s Disease

Status

Suspended

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505096-68-00

Acronym

64042056ALZ2001

Enrollment

151

Registered

2024-10-08

Start date

2025-01-14

Completion date

Unknown

Last updated

2025-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preclinical Alzheimer’s Disease

Brief summary

Change from baseline on PACC-5 total scores at Week 206

Interventions

DRUGflorquinitau F18

DRUGJNJ-64042056

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change from baseline on PACC-5 total scores at Week 206	—

Countries

Belgium, France, Germany, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026